EU or the European Union has just approved the usage of the vaccine to prevent humans from Ebola. The vaccine is called Ervebo, and it is the first of its kind that has been approved by the EU. The European Union has granted the conditional marketing authorization on the Ebola vaccine Ervebo. This one of a kind vaccine has been developed and manufactured by Merck, a pharmaceutical giant in their own right. They have named the vaccine Ervebo, and it is expected to solve most of the problems faced by an Ebola patient. Ervebo is the first drug that has been approved by the EU as an Ebola vaccine for humans. Even though the EU has recently approved the vaccine, the production of Ervebo is not at all recent.
Over a decade ago, the Public Health Agency of Canada, along with the US Army, was the first to engineer this vaccine. There was a massive outbreak of Ebola that took place in West Africa in the year 2014. Following this incident, the rights for the development of Ervebo was acquired by Merck. EU has given the conditional marketing authorization for Ervebo. This type of approval is mainly specified for the medicines that generally handle the medical needs that have been kept unmet for quite some time. Such type of authorization helps the medicine to progress with a few comprehensive details and data than they usually are required. Authorization is only approved for medications where the risks are negligible as compared to the vast benefits in health.
The tests that have been carried out with Ervebo in a preliminary manner have been quite promising. In the trials carried out in Guinea, there was a 100 percent success achieved by this vaccine. With the intent for clinical development, over 250,000 doses of Ervebo were donated to the World Health Organization or WHO by Merck. By the third quarter of 2020, the plans for developing Ervebo have been declared by Merck in Germany. The FDA or Food and Drug Administration of the US is also reviewing this vaccine at present.